Previous 10 | Next 10 |
PHILADELPHIA, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced that Steven Nichtberger, ...
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Stocks ended the week on a down note after the simultaneous expiration of single-stock options, single-stock futures, and stock-index options, and stock-fu...
Gainers: Spruce Biosciences (NASDAQ:SPRB) +30%. Coherus BioSciences (NASDAQ:CHRS) +11%. TPI Composites (NASDAQ:TPIC) +6%. Lyell Immunopharma (NASDAQ:LYEL) +4%. Aquestive Therapeutics (NASDAQ:AQST) +4%. Losers: Adagio Therapeutics (NASDAQ:ADGI) -5%. Leslie's (NASDAQ:LESL) -3%. Rivian Automotiv...
Galera Therapeutics (NASDAQ:GRTX) +15%. Splunk (NASDAQ:SPLK) +7%. Digital World Acquisition (NASDAQ:DWAC) +6%. Momentus (NASDAQ:MNTS) +6%. Cabaletta Bio (NASDAQ:CABA) +6%. Aspen (NASDAQ:ASPU) -21%. Communications Systems (NASDAQ:JCS) -11%. DAVIDsTEA (NASDAQ:DTEA) -6%. BioNTech SE (NASDAQ:BNTX...
Chinese real estate stocks were among the leaders to the downside during Tuesday's weak session on Wall Street. Concerns surrounding Shimao Group (OTCPK:SIOPF) sparked losses across the industry, including notable retreats from Nam Tai Property (NYSE:NTP) and MDJM (NASDAQ:MDJH). The drug deve...
Gainers: Galera Therapeutics (NASDAQ:GRTX) +106%. Nuverra Environmental Solutions (NYSE:NES) +33%. CPS Technologies (NASDAQ:CPSH) +24%. Terminix (NYSE:TMX) +21%. Alzamend Neuro (NASDAQ:ALZN) +17%. MIND Technology (NASDAQ:MIND) +17%. Landec Corporation (NASDAQ:LNDC) +13%. Soliton (NASDAQ:SOLY)...
Gainers: Galera Therapeutics (NASDAQ:GRTX) +116%, Alzamend Neuro (NASDAQ:ALZN) +18%, Soliton (NASDAQ:SOLY) +12%, Kiromic BioPharma (NASDAQ:KRBP) +6%, Biofrontera (NASDAQ:BFRI) +5%. Losers: Adagio Therapeutics (NASDAQ:ADGI) -78%, Adagio Th...
Cabaletta Bio (NASDAQ:CABA) plummets 34.5% premarket after announcing top-line data on biologic activity from the two lowest dose cohorts in the DesCAARTes Phase 1 trial of DSG3-CAART for the treatment of patients with mucosal Pemphigus Vulgaris (mPV). In cohort A1, participants rec...
PHILADELPHIA, Dec. 14, 2021 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today reported top-line data on biologic ...
PHILADELPHIA, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced that the Company will par...
News, Short Squeeze, Breakout and More Instantly...
PHILADELPHIA, July 02, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced that Steven Nichtb...
2024-06-20 09:56:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
– No CRS, ICANS, infections or serious adverse events observed in either of the first two patients through data cut-off of May 28, 2024 – – CABA-201 exhibited anticipated profile of CAR T cell expansion and contraction with complete B cell depletion observed in both...